The most frequent grade 3–4 adverse event during NAC was neutropenia (n = 28, 34%), which was less frequent in patients receiving G-CSF prophylaxis (25% vs. 67%) and was complicated with febrile neutropenia in five patients (6.0%). This evidence concerns the gene CSF3 and neutropenia.